Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-10-13FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Camber Pharmaceuticals Inc.)
FDA approved a supplemental application for methylphenidate hydrochloride from Camber Pharmaceuticals Inc., confirming approval of a generic…
-
FDA approval · 2023-10-13FDA Approved: DEXTROAMPHETAMINE SULFATE — Supplemental Application (Wilshire Pharmaceuticals, Inc.)
FDA approved a supplemental application for dextroamphetamine sulfate by Wilshire Pharmaceuticals, Inc.
-
FDA approval · 2023-10-11FDA Approved: AMPHETAMINE SULFATE — Supplemental Application (Amneal Pharmaceuticals NY LLC)
FDA approved a supplemental application for Amphetamine Sulfate (amphetamine) from Amneal Pharmaceuticals NY LLC under ANDA211139.
-
FDA approval · 2023-10-05FDA Approved: GUANFACINE — Original Application (A2A Integrated Pharmaceuticals)
FDA approved the original application for guanfacine from A2A Integrated Pharmaceuticals, enabling generic guanfacine products to enter the …
-
CLINICAL_TRIALS trial_result · 2023-09-28Clinical Trial Update: Evaluation of the Effect Foquest® on Sleep in Children Aged 6-12 With ADHD [Phase 4]
Phase 4 trial evaluating the effect of Foquest on sleep in children aged 6-12 with ADHD; current status is unknown.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-09-27FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical's original ANDA for a generic mixture of dextroamphetamine and amphetamine salts (dextroamphetamine sacchara…
-
CLINICAL_TRIALS research · 2023-09-21Clinical Trial Update: Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder [Phase 4]
Phase 4 neuroimaging trial investigating risk factors for adolescent bipolar disorder; completed.
-
FDA approval · 2023-09-12FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Camber Pharmaceuticals Inc.)
FDA approved Camber Pharmaceuticals' supplemental application for methylphenidate hydrochloride, resulting in an approved modification to th…
-
FDA approval · 2023-09-12FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Eywa Pharma Inc)
FDA approved Eywa Pharma Inc's supplemental application for methylphenidate hydrochloride.
-
FDA approval · 2023-09-07FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for methylphenidate hydrochloride from Sun Pharmaceutical Industries, authorizing modifications …
-
FDA approval · 2023-08-31FDA Approved: MIXED SALTS OF A SINGLE-ENTITY AMPHETAMINE PRODUCT — Original Application (SpecGx LLC)
FDA approved an original ANDA for a mixed-salts amphetamine product by SpecGx LLC, comprising multiple dextroamphetamine/amphetamine salts.
-
FDA approval · 2023-08-25FDA Approved: LISDEXAMFETAMINE DIMESYLATE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' lisdexamfetamine dimesylate as an original-application generic product under ANDA 217068.
-
FDA approval · 2023-08-25FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Granules Pharmaceuticals Inc.)
The FDA approved a supplemental application from Granules Pharmaceuticals Inc. for dexmethylphenidate hydrochloride granules, expanding the …
-
FDA approval · 2023-08-25FDA Approved: LISDEXAMFETAMINE DIMESYLATE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approves lisdexamfetamine dimesylate (generic) from Mylan as an Original Application; the generic is approved for the same indications a…
-
FDA approval · 2023-08-25FDA Approved: LISDEXAMFETAMINE DIMESYLATE — Original Application (SpecGx LLC)
FDA approved lisdexamfetamine dimesylate under an Original Application (generic) filed by SpecGx LLC.
-
FDA approval · 2023-08-25FDA Approved: LISDEXAMFETAMINE DIMESYLATE — Original Application (Alvogen Inc.)
FDA approved the original ANDA for lisdexamfetamine dimesylate (generic) from Alvogen, enabling a generic version of the ADHD and binge eati…
-
FDA approval · 2023-08-25FDA Approved: LISDEXAMFETAMINE DIMESYLATE — Original Application (Teva Pharmaceuticals, Inc.)
The FDA approved Teva's original ANDA for lisdexamfetamine dimesylate, establishing a generic version of the prodrug used to treat ADHD and …
-
FDA approval · 2023-08-25FDA Approved: LISDEXAMFETAMINE DIMESYLATE — Original Application (Rhodes Pharmaceuticals)
FDA approved an original generic application for lisdexamfetamine dimesylate from Rhodes Pharmaceuticals for the treatment of ADHD and binge…
-
FDA approval · 2023-08-25FDA Approved: LISDEXAMFETAMINE DIMESYLATE — Original Application (Lannett Company, Inc.)
FDA approves the original application for lisdexamfetamine dimesylate as a generic drug by Lannett Company, enabling generic supply with the…
-
FDA approval · 2023-08-25FDA Approved: LISDEXAMFETAMINE DIMESYLATE — Original Application (Camber Pharmaceuticals, Inc.)
FDA lists Camber Pharmaceuticals' lisdexamfetamine dimesylate as an approved original application (generic) product. The approval covers the…
-
FDA approval · 2023-08-25FDA Approved: LISDEXAMFETAMINE DIMESYLATE — Original Application (Amneal Pharmaceuticals LLC)
FDA approves Amneal Pharmaceuticals LLC's original application for lisdexamfetamine dimesylate as a generic drug. This approval provides a g…
-
FDA approval · 2023-08-25FDA Approved: LISDEXAMFETAMINE DIMESYLATE — Original Application (Apotex Corp.)
FDA approves Apotex Corp.'s lisdexamfetamine dimesylate as a generic version of the ADHD and binge eating disorder medication.
-
FDA approval · 2023-08-25FDA Approved: LISDEXAMFETAMINE DIMESYLATE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a generic lisdexamfetamine dimesylate product under an Original ANDA for the treatment of ADHD and binge-eating disorder.
-
FDA approval · 2023-08-25FDA Approved: LISDEXAMFETAMINE DIMESYLATE — Original Application (Solco Healthcare US,LLC)
FDA approved Solco Healthcare US, LLC's lisdexamfetamine dimesylate capsules as an original generic application (ANDA) for ADHD and binge ea…
-
FDA approval · 2023-08-25FDA Approved: LISDEXAMFETAMINE DIMESYLATE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approves Sun Pharmaceutical's lisdexamfetamine dimesylate as an original generic application, confirming a generic version of the stimul…